Drug Pricing Practices In Canada, Germany May Stifle Innovation – USTR Report
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. Trade Representative cites Canadian procedures that allow "infringing" generic drugs on the market in adding the country to its IP "watch list." The report expresses concern about Germany's development of a reference pricing system, which would lump brands with generics.